Literature DB >> 25372646

[Adult Sturge-Weber syndrome without facial hemangioma: report of one case].

Rong Zhang1, Wei Chen1, Qiang Hu2, Sudeep Shrestha2.   

Abstract

Sturge-Weber syndrome (SWS) is characterized by angiomas affecting the ophthalmic division of the trigeminal nerve, epilepsy, intellectual impairment, hemiplegia and glaucoma. We report a patient who developed SWS without facial hemangioma (SWS type III) in his adulthood. The patient presented with repeated episodes of headache since age 37 year. He manifested first attack of seizure at the age 47 year followed by aphasia and right upper limb palsy. Brain CT scan revealed right parietal-occipital calcification, brain CT angiography showed right temporal lobe and occipital lobe vascular malformation, and MRI showed leptomeningeal enhancement in the riht cerebral piamater. The seizure was controlled with antiepileptic drugs and reviewed in routine follow up.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25372646     DOI: 10.3785/j.issn.1008-9292.2014.04.005

Source DB:  PubMed          Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban        ISSN: 1008-9292


  2 in total

1.  Consensus Statement for the Management and Treatment of Sturge-Weber Syndrome: Neurology, Neuroimaging, and Ophthalmology Recommendations.

Authors:  Sara Sabeti; Karen L Ball; Sanjoy K Bhattacharya; Elena Bitrian; Lauren S Blieden; James D Brandt; Craig Burkhart; Harry T Chugani; Stephen J Falchek; Badal G Jain; Csaba Juhasz; Jeffrey A Loeb; Aimee Luat; Anna Pinto; Eric Segal; Jonathan Salvin; Kristen M Kelly
Journal:  Pediatr Neurol       Date:  2021-05-06       Impact factor: 4.210

2.  Isolated leptomeningeal angiomatosis in the sixth decade of life, an adulthood variant of Sturge Weber Syndrome (Type III): role of advanced Magnetic Resonance Imaging and Digital Subtraction Angiography in diagnosis.

Authors:  Vetrivel Muralidharan; Gaetano Failla; Mario Travali; Tiziana Liliana Cavallaro; Marco Angelo Politi
Journal:  BMC Neurol       Date:  2020-10-06       Impact factor: 2.474

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.